ArticleRSC advances2024
Nanodrug delivery system constructed with dopamine-based functional molecules for efficient targeting of tumour cells.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming barriers: mechanisms and strategies of nanoparticles in overcoming the blood-brain barrier and drug resistance in glioblastomas.Journal of the Egyptian National Cancer Institute · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to enhance the water solubility of chemotherapeutic drugs, improve their biodistribution and narrow therapeutic window, two molecules of PDAO and FA-DAO with acid-sensitive Schiff base structure were designed and synthesized based on dopamine linolenate (DAO) in this paper, and subsequently drug-loaded nanoparticles were prepared by simply mixing of them with curcumin (Cur) in aqueous solution. These nanoparticles can release a large amount of the drug in response to pH changes in the tumor microenvironment through passive targeting. The cumulative rate of drug release can reach up to 70% within 24 hours under pH = 5.0 conditions as a release medium. Furthermore, the drug-carrying nanoparticles achieve active targeting through folic acid (FA) on their surface, which further enhances targeting efficiency. The inhibitory effect of drug-loaded nanoparticles was nearly 8-fold enhanced than that of its loaded Active Pharmaceutical Ingredient (API) Cur on HepG2 cell lines at the administration concentration of 6.25 μg mL
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.